{"name":"Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.","slug":"sichuan-kelun-biotech-biopharmaceutical-co-ltd","ticker":"","exchange":"","domain":"sichuankelunbiopharmaceutical.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"oncology","drugs":[{"name":"KL-A167","genericName":"KL-A167","slug":"kl-a167","indication":"Non-small cell lung cancer","status":"phase_3"},{"name":"A166","genericName":"A166","slug":"a166","indication":"Non-small cell lung cancer","status":"phase_3"},{"name":"Open single period A140","genericName":"Open single period A140","slug":"open-single-period-a140","indication":"Relapsed or refractory acute myeloid leukemia","status":"phase_3"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"immunology","drugs":[{"name":"SKB264","genericName":"SKB264","slug":"skb264","indication":"Other","status":"phase_3"},{"name":"KL340399 Intratumoral","genericName":"KL340399 Intratumoral","slug":"kl340399-intratumoral","indication":"Other","status":"phase_1"}]},{"name":"Metabolic","slug":"metabolic","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"cardiovascular","drugs":[{"name":"Double blind control period A140","genericName":"Double blind control period A140","slug":"double-blind-control-period-a140","indication":"Type 2 diabetes","status":"phase_3"}]}],"pipeline":[{"name":"KL-A167","genericName":"KL-A167","slug":"kl-a167","phase":"phase_3","mechanism":"KL-A167 is a humanized monoclonal antibody targeting PD-L1 to enhance anti-tumor immune responses by blocking the interaction between PD-L1 and PD-1/B7-1.","indications":["Non-small cell lung cancer","Other solid tumors (under investigation in Phase 3)"],"catalyst":""},{"name":"SKB264","genericName":"SKB264","slug":"skb264","phase":"phase_3","mechanism":"SKB264 is a biopharmaceutical agent in development by Sichuan Kelun-Biotech, currently in phase 3 clinical trials.","indications":[],"catalyst":""},{"name":"A166","genericName":"A166","slug":"a166","phase":"phase_3","mechanism":"A166 is an anti-PD-L1 monoclonal antibody that blocks the interaction between PD-L1 on tumor cells and PD-1/B7.1 on immune cells, thereby restoring anti-tumor immune responses.","indications":["Non-small cell lung cancer","Other solid tumors (under investigation in Phase 3)"],"catalyst":""},{"name":"Double blind control period A140","genericName":"Double blind control period A140","slug":"double-blind-control-period-a140","phase":"phase_3","mechanism":"A140 is a small molecule that targets the SGLT2 receptor.","indications":["Type 2 diabetes"],"catalyst":""},{"name":"KL340399 Intratumoral","genericName":"KL340399 Intratumoral","slug":"kl340399-intratumoral","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Open single period A140","genericName":"Open single period A140","slug":"open-single-period-a140","phase":"phase_3","mechanism":"A140 is a monoclonal antibody targeting CD47.","indications":["Relapsed or refractory acute myeloid leukemia","Relapsed or refractory non-Hodgkin lymphoma"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.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?oc=5","date":"2026-03-27","type":"pipeline","source":"simplywall.st","summary":"Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (HKG:6990) Analysts Are Cutting Their Estimates: Here's What You Need To Know - simplywall.st","headline":"Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (HKG:6990) Analysts Are Cutting Their Estimates: Here's What You Need ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi_wFBVV95cUxNVVo3YU80bTFOOWZaZ2w1SlZzVU1WM1ZrbmtJT2RBaDlnclRoRFBpT1BucThFM3BQUHA0a1FDdXNPRVc5RFZvNWloNi1SX3UwMHRtVTJJSDNBVEVHR0QyYUViR3pTdVNzQkV4VXdUTnV4Q2dYdUZOV1dvSkVaQlpUOFhHZnpIdzA5TVh5ZTBHX0FxMklBUFZRTDNDek50SUtwcmFrOWt6M3dCU2tXSkdkRldyZ1dCM3NLNW51MnM4eHlLWk14djliM1J0b09udjFfQXJHdC1uZFQtcWVRMlg0c0hOclNYVlhQWGpOd1NpSUt2Sm11OENYX29JQnB6ek0?oc=5","date":"2026-03-24","type":"pipeline","source":"Thailand Business News","summary":"KELUN-BIOTECH ANNOUNCED 2025 ANNUAL RESULTS: MULTIPLE PRODUCTS SUCCESSFULLY LAUNCHED WITH TIERED PIPELINE READY FOR TAKE-OFF - Thailand Business News","headline":"KELUN-BIOTECH ANNOUNCED 2025 ANNUAL RESULTS: MULTIPLE PRODUCTS SUCCESSFULLY LAUNCHED WITH TIERED PIPELINE READY FOR TAKE","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMizAFBVV95cUxPMGJLZHd3bk1ReW1ZajBwNGRlWlZ3dEtMYVNlWTdxS0pIaHFZWFl0LTMycllCY0RnRGluS3NxQTN2WF9ReGwxREJDUHRmbmR3cW9FbkRKalZQbVpuLVFrWnBsc0M3Ynhlelc2NzJrUk93N3RKZURfS3Q3QmE1b0VGVUdZWENlczkyc2RBNk9LWFVzLVB1bFY1bDdEVEhiZDNxVTR3M2l2cXpDWUplNkdtT2pPNmxxZ0tQYmgxSGIyakp0M05sbGlYdHlKM2o?oc=5","date":"2026-02-09","type":"regulatory","source":"BioPharma APAC","summary":"Kelun Biotech Wins China Approval For Sacituzumab Tirumotecan In Advanced Breast Cancer - BioPharma APAC","headline":"Kelun Biotech Wins China Approval For Sacituzumab Tirumotecan In Advanced Breast Cancer","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMi5wFBVV95cUxPSTVsXzdsMXMyUkVwTEIxN2ZBcERSSVhoZWtwckpvUFRtazZpcU53MHkyUFJNRmFsQ1gtTjZDWDlhLXc0WjUzazRCTHNjLWZfTXVkSWlsYVVfaGRjZWVJZ0xiWmMwRkw2Uzk3STloSGJsdmw4TjY1ZG91cUlnWnVoNHpndTEwR1pnMnlwTVRYdkE3SlJJOHZxa0x4NmZfc21hRjFyNl9ST1hVVk45a0FudkZ4OGg3bWpqVEc3WUtfYTNjY3RQak1HazItcGJBMnQxQnZ6TnlLWkxrdW1ZOUJPV3NNVjFBZ0U?oc=5","date":"2026-01-07","type":"regulatory","source":"BioPharma APAC","summary":"Sichuan Kelun Biotech Secures NMPA IND Approval For SKB105 Antibody Drug Conjugate In Advanced Solid Tumours - BioPharma APAC","headline":"Sichuan Kelun Biotech Secures NMPA IND Approval For SKB105 Antibody Drug Conjugate In Advanced Solid Tumours","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMipwFBVV95cUxNMW1HWGJMWlo5dEdhYUFIaUNGWHlvN1N6Vkp6ZUF5bm9NU2I5SENjM2tyZXRMS05aUm5RaXBiXzhGLUpHNURTZ19oZWF4WWdSb08xa1pWY01UdjAyX3U0ZXM0cm00MTRfUXVBRnJFVnlZNnEtRk9YVWRDaW14SlhvODVfZ2hGVlhVWDBQdjNsYjExZmRBQ2RWZ2F4dFhUcm9SRERpcUp5RQ?oc=5","date":"2025-12-23","type":"pipeline","source":"BioWorld News","summary":"Big pharma taps fast Asia innovation in search of next Keytruda - BioWorld News","headline":"Big pharma taps fast Asia innovation in search of next Keytruda","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipAFBVV95cUxOMWxkWGgyMy1vTHNES3otZEF2X3ZGbEZYdExIWlp3ZE9ycmE1akZZMm1OTmlRNW1kcnNOT0RaODZJOTRqRVRnNHB2X1NhVllpNWoxZlhnSm1iVGd3bjd2THpSTnFNMWxqY0JXVXhvUXRPMlVTdVFqSVN2NjN3Z3B1ZmY5U0h6bnpGc1B1d3NKX3ZJbFpaWW1rblBvT3BSbHdlZXkwTQ?oc=5","date":"2025-12-09","type":"deal","source":"BioWorld News","summary":"Crescent, Kelun in two-way deal, including PD-1/VEGF bispecific - BioWorld News","headline":"Crescent, Kelun in two-way deal, including PD-1/VEGF bispecific","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi0wFBVV95cUxNSXZzNC1BakFSR3VueURMcU5jbTdkb2NlN3Voc3lud2k3OE5kVGx6eldjeUpUN3pLeWxXSUdNN2R0cTFqRWFnWkVqdjRXcU00MW9BdmVTTTB2V0lEcm4wcXpXeE9aaEM2VU1yNU9KWm9tUWVMSTNJUDFXUGUzcGgzV1pjUk85V015VDNZOFc1dnk5cWpOdXNlbHEwc3AzMU5jVTZ1cjZTaDFGWTJISDhXN0w1Q00ybkFJV3hzaDM1NjF0emxGN1FMRFY3R2pWYjJmeEdr?oc=5","date":"2025-12-05","type":"deal","source":"Reuters","summary":"China's Kelun-Biotech licenses cancer treatment to Crescent Biopharma - Reuters","headline":"China's Kelun-Biotech licenses cancer treatment to Crescent Biopharma","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi5gFBVV95cUxPLXlPMldHUVJvQ2o2cGN0RnVtX2RyNnRzb0lYemFZUHR4Wk93OWRvU01kYWFjUC1FbTYyZU9TcGw2MWF6R2hOcFdWdUtWbEkwc0JkVDh1SGF4N3duS1F4OUNabjNKTU96aWdGVWFvaXdFZEZwdWhwM1UybjJxSUIwdjZabjBKZ2s3aHdyWUhseWwwV2M2UVcxLTZ6SnoySkQzbWR0VTdYQXdKc1pXeHJzNTItNk5vaGRjZ3lqUUczVjA4ZHRja09VVjgtejFtQ2U1RXF1OGw4eFdMdHhwVlRBbml3dEx2QQ?oc=5","date":"2025-12-05","type":"deal","source":"BioPharma APAC","summary":"Kelun Biotech And Crescent Biopharma Forge Global Partnership To Advance Next Generation Oncology Therapies - BioPharma APAC","headline":"Kelun Biotech And Crescent Biopharma Forge Global Partnership To Advance Next Generation Oncology Therapies","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikwJBVV95cUxQS0tfMGtOUHdtR3JRYjFtMHlrMlcycTJBdzFfeDJxU2xTTDlQb0lMNXFQNi1sOXowSUFadkpkTVlkYVFCZEdZc1NzS2hCa0dZeHR1OTg0Ni1xR0Izam96V1VGVDREV1RLLXFZNm9MS1lMR2RCM2tqRjl6MnlaNHlJQ2lJYXR1VXBhQ2tIZWVnSTkwSkVrLVdYTEpRa005clBjVzRHZFRBUUtsY1pOMmVOcThHV01vanJEazFrUTdWaFA0UlBYLTNIcUF6Q3NpVkM0elg1MkluT2hsRXB3OUo4Nk1sUTF2ZE5LaHBiWGRORWVtdThmYW9KRThuUEtRejNPU2hNd09zWjQ0RWYtS05nNFgyZw?oc=5","date":"2025-12-04","type":"deal","source":"prnewswire.com","summary":"Kelun-Biotech and Crescent Biopharma Announce Strategic Partnership to Develop and Commercialize Novel Oncology Therapeutics - prnewswire.com","headline":"Kelun-Biotech and Crescent Biopharma Announce Strategic Partnership to Develop and Commercialize Novel Oncology Therapeu","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi9AFBVV95cUxQNUZzbWM2Z04wbUJlQkZCSFh2SHZuaWxaM0xfVmV6WTYxTDhGTUxnS0ZMeVRHNjNsTzM4am1BdDBlMG1XWjVqa1ppb2pmbVY4RjlseGVnQldnenRSVkpYRFZvTWFHaUJxaEgxVWdZZktNSlgzRlZhNW5wal9rbXdYZ3FGQlpaZ2NsQ1JmRGpnNzBMZDJKVmlpYy16MjNqa0ZEdUQ0U0xGVWlkeTJIbU4xWnBBdDdVQkhpXzd1NFRzLXpEZDJKVklTYlNDbEp2VWFzc2JIVzFMVUN3LVUzM2lWNW9TUVlTMS1pN1lpazhwXzR3eC1I?oc=5","date":"2025-10-17","type":"regulatory","source":"prnewswire.com","summary":"Kelun-Biotech's Core product Trastuzumab Botidotin Approved for Marketing by NMPA for HER2-positive BC - prnewswire.com","headline":"Kelun-Biotech's Core product Trastuzumab Botidotin Approved for Marketing by NMPA for HER2-positive BC","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMi3AJBVV95cUxOVzUyMTV0S3dDRHBxYTl0OHVGVDhDVUZYUVVRMmJteU5LSWd2UVlzd3laN192N05saWxuMVhOa0l2RHhaRWlabHhkUEdtcUctVnY2WnFqRGhubDZ3OHVKOUprbkFjY3FlS0RSWVRubXpuRVgyNHJPNmIwZk5ZLXgwVXJ6Y1FLWkFaeFliQm9sSVJNY3FUN2pRTms3TVp1Q2s2d1BuQXhHVWZmVkdlUE03RzZ5NEhWZUh0NlJ3UEowbmFuZ0ROdVppd0RUdVBCY3o3S3dxTHl4b1hjeTc1WlVIVExadXdMOFNZdnNGTmdCV2YzamZOVnN1N25NZEQ1VFZ5Mk9fMEtvZ1U3VU9mbUJYRXVKYm04QVc4Q2JpY0JPVEx3X1pnX1JZSGRkMnFnVEdfajJSNkczMHVSV1ZTUklpc0hocjYwNnJrOFZuMkFCRTNrSlJ4LVpka1B3OWM?oc=5","date":"2025-09-23","type":"pipeline","source":"prnewswire.com","summary":"Kelun-Biotech's New Drug Application for Its Novel Next-generation Selective RET Inhibitor A400/EP0031 Accepted for Review by the NMPA for the Treatment of RET-fusion positive NSCLC - prnewswire.com","headline":"Kelun-Biotech's New Drug Application for Its Novel Next-generation Selective RET Inhibitor A400/EP0031 Accepted for Revi","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilgFBVV95cUxQckRrOUJqZU5kYUxBRS13ZW1qVWs0b0pkRVBlNG1BWXB2Rm02NWxsRmQya1dqbHNWcHVRMEtrdkRYUjJMOWVCdHgtLWpyRTgwY1M4VWROMDJTSTRkbXdPY0RibDFMZUZQaFRfMVlRdTJWVE4tN2pWaUZDem1VTXROcUF5YTJOX1JrSjVrbHdOdk5USXdsTHc?oc=5","date":"2025-08-18","type":"pipeline","source":"Plataforma Media","summary":"KELUN-BIOTECH ANNOUNCES 2025 INTERIM RESULTS - Plataforma Media","headline":"KELUN-BIOTECH ANNOUNCES 2025 INTERIM RESULTS","sentiment":"neutral"}],"patents":[],"drugCount":6,"phaseCounts":{"phase_3":5,"phase_1":1},"enrichmentLevel":0,"visitCount":4,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}